Q2 2026 saw 11% reported and 6% organic sales growth, with strong Prosthetics & Neuro Orthotics performance and improved EBITDA margin at 22%. Net profit rose 39% year-over-year, and free cash flow was robust. Guidance for 2026 organic sales growth narrowed to 5-7%.

Original document:

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.